Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fidia farmaceutici s.p.a., taliansko - kyselina hyalurónová - 29 - antirheumatica, antiphlogistica, antiuratica

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

abbvie s.r.o., slovensko - botulotoxín - 63 - myorelaxantia

Slovacia - slovacă - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline biologicals s.a., belgicko - očkovacia látka proti chrípke, inaktivovaná, štiepený vírus alebo povrchový antigén - 59 - immunopraeparata

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Uniunea Europeană - slovacă - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritída, reumatoidná artritída - imunosupresíva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant sa môže používať ako monoterapia alebo v kombinácii s metotrexátom. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

phibro animal health, poľsko - tbl.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

huvepharma nv, belgicko - gran.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

chanelle pharmaceuticals manufacturing, Írsko - sol.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

chanelle pharmaceuticals manufacturing, Írsko - sol.

Slovacia - slovacă - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

chanelle pharmaceuticals manufacturing, Írsko - sol.